Merck (MRK) shares dipped 0.3% in early trading on Friday. According to the Financial Times, the company is in talks for a potential multi-billion dollar deal to acquire Revolution Medicines (RVMD), coming just one day after AbbVie (ABBV) stated it was not engaged in discussions with the biotechnology firm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments